Literature DB >> 21239499

Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function.

Yosuke Kanno1, Akira Ishisaki, Eri Kawashita, Naoyuki Chosa, Keiichi Nakajima, Tatsuji Nishihara, Kuniaki Toyoshima, Kiyotaka Okada, Shigeru Ueshima, Kenji Matsushita, Osamu Matsuo, Hiroyuki Matsuno.   

Abstract

The contribution of plasminogen (Plg)/plasmin, which have claimed to be the main fibrinolytic regulators in the bone metabolism, remains unclear. This study evaluated how the absence of Plg affects the function of osteoblast (OB) and osteoclast (OC). There was a larger population of pre-OCs in bone marrow-derived cells from the Plg(-/-) mice than the population of that from the WT mice. In addition, the absence of Plg suppressed the expression of osteoprotegerin in OBs. Moreover, an exogenous plasmin clearly induced the osteoprotegerin expression in Plg(-/-) OBs. The osteoclastogenesis of RAW264.7 mouse monocyte/macrophage lineage cells in co-culture with OBs from the Plg(-/-) mice was significantly accelerated in comparison with that in co-culture with OBs from the WT mice. Intriguingly, the accelerated OC differentiation of RAW264.7 cells co-cultured with Plg(-/-) OBs was clearly suppressed by the treatment of an exogenous plasmin. Consequently, Plg(-/-) mice display decreased bone mineral density. These findings could eventually lead to the development of new clinical therapies for bone disease caused by a disorder of the fibrinolytic system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239499      PMCID: PMC3059016          DOI: 10.1074/jbc.M110.152181

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency.

Authors:  E Daci; A Verstuyf; K Moermans; R Bouillon; G Carmeliet
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

2.  Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin alpha(9)beta(1).

Authors:  Mousumi Majumdar; Takehiko Tarui; Biao Shi; Nobuaki Akakura; Wolfram Ruf; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2004-07-06       Impact factor: 5.157

3.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.

Authors:  T Nakashima; Y Kobayashi; S Yamasaki; A Kawakami; K Eguchi; H Sasaki; H Sakai
Journal:  Biochem Biophys Res Commun       Date:  2000-09-07       Impact factor: 3.575

4.  Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects.

Authors:  K Thirunavukkarasu; R R Miles; D L Halladay; X Yang; R J Galvin; S Chandrasekhar; T J Martin; J E Onyia
Journal:  J Biol Chem       Date:  2001-07-12       Impact factor: 5.157

Review 5.  Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Authors:  L C Hofbauer; A E Heufelder
Journal:  J Mol Med (Berl)       Date:  2001-06       Impact factor: 4.599

6.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

Authors:  J Li; I Sarosi; X Q Yan; S Morony; C Capparelli; H L Tan; S McCabe; R Elliott; S Scully; G Van; S Kaufman; S C Juan; Y Sun; J Tarpley; L Martin; K Christensen; J McCabe; P Kostenuik; H Hsu; F Fletcher; C R Dunstan; D L Lacey; W J Boyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Increased bone formation in mice lacking plasminogen activators.

Authors:  E Daci; V Everts; S Torrekens; E Van Herck; W Tigchelaar-Gutterr; R Bouillon; G Carmeliet
Journal:  J Bone Miner Res       Date:  2003-07       Impact factor: 6.741

8.  Lack of alpha 2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice.

Authors:  Hiroyuki Matsuno; Akira Ishisaki; Keiichi Nakajima; Kiyotaka Okada; Shigeru Ueshima; Osamu Matsuo; Osamu Kozawa
Journal:  Blood       Date:  2003-07-31       Impact factor: 22.113

9.  Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus.

Authors:  J V Braaten; S Handt; W G Jerome; J Kirkpatrick; J C Lewis; R R Hantgan
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

10.  Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin.

Authors:  R M Lyons; L E Gentry; A F Purchio; H L Moses
Journal:  J Cell Biol       Date:  1990-04       Impact factor: 10.539

View more
  16 in total

1.  Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria.

Authors:  Kukiat Tudpor; Sergio Laínez; Arjan J Kwakernaak; Nadezda V Kovalevskaya; Sjoerd Verkaart; Siebe van Genesen; Annemiete van der Kemp; Gerjan Navis; René J M Bindels; Joost G J Hoenderop
Journal:  J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 10.121

2.  Plasminogen Regulates Fracture Repair by Promoting the Functions of Periosteal Mesenchymal Progenitors.

Authors:  Luqiang Wang; Lutian Yao; Hao Duan; Fan Yang; Maohuan Lin; Rongxin Zhang; Zhenqiang He; Jaimo Ahn; Yi Fan; Ling Qin; Yanqing Gong
Journal:  J Bone Miner Res       Date:  2021-09-08       Impact factor: 6.741

3.  Fibrin accumulation secondary to loss of plasmin-mediated fibrinolysis drives inflammatory osteoporosis in mice.

Authors:  Heather A Cole; Tetsuro Ohba; Jeffry S Nyman; Haro Hirotaka; Justin M M Cates; Matthew J Flick; Jay L Degen; Jonathan G Schoenecker
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

4.  Targeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasis.

Authors:  Yiwei Li; Dejuan Kong; Aamir Ahmad; Bin Bao; Fazlul H Sarkar
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

5.  uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca(2+)/CaMKK/AMPK Axis.

Authors:  Yosuke Kanno; Akira Ishisaki; Eri Kawashita; Hiromi Kuretake; Kanako Ikeda; Osamu Matsuo
Journal:  Int J Biol Sci       Date:  2016-01-01       Impact factor: 6.580

6.  uPA-derived peptide, Å6 is involved in the suppression of lipopolysaccaride-promoted inflammatory osteoclastogenesis and the resultant bone loss.

Authors:  Yosuke Kanno; Chihiro Maruyama; Ayaka Matsuda; Akira Ishisaki
Journal:  Immun Inflamm Dis       Date:  2017-05-11

7.  Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis.

Authors:  Hui Li; Jing Wang; Qiwen Sun; Gang Chen; Shengnan Sun; Xuemei Ma; Haiwen Qiu; Xuerong Liu; Liangyi Xu; Mei Liu
Journal:  Int J Mol Sci       Date:  2018-11-21       Impact factor: 5.923

8.  Trps1 transcription factor represses phosphate-induced expression of SerpinB2 in osteogenic cells.

Authors:  Mairobys Socorro; Apurva Shinde; Hajime Yamazaki; Sana Khalid; Daisy Monier; Elia Beniash; Dobrawa Napierala
Journal:  Bone       Date:  2020-10-03       Impact factor: 4.398

9.  Correlations Between Abnormal Glucose Metabolism and Bone Mineral Density or Bone Metabolism.

Authors:  Yang Qu; Ming-Yang Kang; Rong-Peng Dong; Jian-Wu Zhao
Journal:  Med Sci Monit       Date:  2016-03-13

10.  The blocking of uPAR suppresses lipopolysaccharide-induced inflammatory osteoclastogenesis and the resultant bone loss through attenuation of integrin β3/Akt pathway.

Authors:  Yosuke Kanno; Akira Ishisaki; Mei Miyashita; Osamu Matsuo
Journal:  Immun Inflamm Dis       Date:  2016-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.